Adolescent HIV-1 transgenic rats: Evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge

Current HIV Research

Volumn 10, Issue 5, 2012, Pages 415-424

  Moran, Landhing M ^a   Aksenov, Michael Y ^a   Booze, Rosemarie M ^a   Webb, Katy M ^a   Mactutus, Charles F ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

AIDS; Dopamine; Hand; HIV 1 Tg rat; MAO A; Methamphetamine; Prepulse inhibition; Sensorimotor gating; Tyrosine hydroxylase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE;

ACOUSTIC REFLEX; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BODY WEIGHT; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; GENE EXPRESSION; GROUPS BY AGE; HABITUATION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MESENCEPHALON; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NOISE; NONHUMAN; PREDICTIVE VALUE; PREPULSE INHIBITION; RAT; SENSORY GATING; STARTLE REFLEX; STIMULUS RESPONSE; TRANSGENIC RAT; WASTING SYNDROME; WESTERN BLOTTING;

ACOUSTIC STIMULATION; ANIMALS; BLOTTING, WESTERN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; HIV-1; MALE; MESENCEPHALON; METHAMPHETAMINE; MONOAMINE OXIDASE; PREDICTIVE VALUE OF TESTS; RATS; RATS, TRANSGENIC; SENSORY GATING; STARTLE REACTION; TYROSINE 3-MONOOXYGENASE;

EID: 84866111830     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212802138788     Document Type: Article

References (71)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 789-799.
2. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort study:1990-1998. Neurology 2001; 56: 257-260.
3. Heaton RK, Clifford DB, Franklin DR Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010; 75: 2087-2096.
4. Castello E, Baroni N, Pallestrini E. Neurotological auditory brain stem response findings in human immunodeficiency virus-positive patients without neurologic manifestations. Ann Otol Rhinol Laryngol 1998; 107: 1054-1060.
5. Fein G, Biggins CA, MacKay S. Delayed latency of the eventrelated brain potential P3A component in HIV disease. Progressive effects with increasing cognitive impairment. Arch Neurol 1995; 52: 1109-1118.
6. Gil R, Breux JP, Neau JP, Becq-Giraudon B. Cognitive evoked potentials and HIV infection Neurophysiol Clin 1992; 22: 385-391.
7. Goodwin GM, Pretsell DO, Chiswick A, Egan V, Brettle RP. The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case-control study of the evolution of dementia. AIDS 1996; 10: 431-440.
8. Ollo C, Johnson R, Jr., Grafman J. Signs of cognitive change in HIV disease: an event-related brain potential study. Neurology 1991; 41: 209-215.
9. Pagano MA, Cahn PE, Garau ML, et al. Brainstem auditory evoked potentials in human immuno-deficiency virus-seropositive patients with and without acquired immunodeficiency syndrome. Archives of Neurology 1992; 49: 166-169.
10. Schroeder MM, Handelsman L, Torres L, Jacobson J, Ritter W. Consistency of repeated event-related potentials in clinically stable HIV-1-infected drug users. J Neuropsychiatry Clin Neurosci 1996; 8: 305-310.
11. Vigliano P, Boffi P, Bonassi E, et al. Neurophysiologic exploration: a reliable tool in HIV-1 encephalopathy diagnosis in children. Panminerva Med 2000; 42: 267-272.
12. Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B. Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 1994; 8: 67-71.
13. Berger JR, Nath A. HIV dementia and the basal ganglia. Intervirology 1997; 40: 122-131.
14. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P. Parkinsonism in HIV dementia. J Neural Transm 2002; 109: 767-775.
15. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J Neurovirol 2011; 17: 26-40.
16. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virusinfected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10: 350-357.
17. Garvey LJ, Yerrakalva D, Winston A. Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy. AIDS Res Hum Retroviruses 2009; 25: 765-769.
18. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17:3-16.
19. di Rocco A, Bottiglieri T, Dorfman D, Werner P, Morrison C, Simpson D. Decrease homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1 infected patients. Clin Neuropharmacol 2000; 23: 190-194.
20. Wang GJ, Chang L, Volkow ND, et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 2004;127: 2452-2458.
21. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002; 67: 53-83.
22. Chudasama Y, Robbins TW. Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol. Psychol 2006; 73: 19-38.
23. Aksenov MY, Aksenova MV, Silvers JM, Mactutus CF, Booze RM. Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons. Neurotoxicology 2008; 29: 971-977.
24. Zhu J, Mactutus CF, Wallace DR, Booze RM. HIV-1 Tat proteininduced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2betacarbomethoxy- 3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 2009; 329: 1071-1083.
25. Zhu J, Ananthan S, Mactutus CF, Booze RM. Recombinant human immunodeficiency virus-1 transactivator of transcription(1-86) allosterically modulates dopamine transporter activity. Synapse 2011; 65: 1251-1254.
26. Ferris MJ, Frederick-Duus DF, Fadel J, Mactutus CF, Booze RM. Hyperdopaminergic tone in HIV-1 protein treated rats and cocaine sensitization. J Neurochem 2010; 115: 885-896.
27. Aksenova MV, Silvers JM, Aksenov MY, et al. HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci Lett 2006; 395: 235-239.
28. Wallace DR, Dodson S, Nath A, Booze RM. Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 2006; 59: 51-60.
29. Silvers JM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM. Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor. Neurotoxicology 2007; 28: 1184-1190.
30. Ferris MJ, Mactutus CF, Booze, RM. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: Current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev 2008; 32: 883-909.
31. Purohit V, Rapaka R, Shurtleff D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 2011; 44: 102-110.
32. Chang L, Ernst T, Speck O, Grob CS. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 2005; 162: 361-369.
33. Carey CL, Woods SP, Rippeth JD, Gonzalez R, Heaton RK, Grant I. Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav 2006; 10: 185-190.
34. Rippeth JD, Heaton RK, Carey CL, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 2004; 10: 1-14.
35. Koch M, Schnitzler HU. The acoustic startle response in rats-circuits mediating evocation, inhibition and potentiation. Behav Brain Res 1997; 89: 35-49.
36. Fendt M, Li L, Yeomans JS. Brain stem circuits mediating prepulse inhibition of the startle reflex. Psychopharmacology 2001; 156: 216-224.
37. Hoffman HS, Ison JR. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychological Review 1980; 87: 175-189.
38. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001; 156: 117-154.
39. Hadmitzky M, Markou A, Kuczenski R. Extended access to methamphetamine self-administration affects sensorimotor gating in rats. Behav Brain Res 2011; 217: 386-390.
40. Reid W, Sadowska M, Denaro F, et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci USA 2001; 98: 9271-9276.
41. Peng J, Vigorito M, Liu X, Zhou D, Wu X, Chang SL. The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. J Neuroimmunol 2010; 218: 94-101.
42. Vigorito M, Lashomb AL, Chang SL. Spatial learning and memory in HIV-1 transgenic rats. J Neuroimmune Pharmacol 2007; 2: 319-328.
43. Lashomb AL, Vigorito M, Chang SL. Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. J Neurovirol 2009; 15: 14-24.
44. Joshi PC, Raynor R, Fan X, Guidot DM. HIV-1-transgene expression in rats decreases alveolar macrophage zinc levels and phagocytosis. Am J Respir Cell Mol Biol 2008; 39: 218-226.
45. Lassiter C, Fan X, Joshi PC, et al. HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. AIDS Res Ther 2009; 6: 1.
46. Tipton KF, Boyce S, O'Sullivan J, Davey GP, Healy J. Monoamine oxidases: certainties and uncertainties. Curr Med Chem 2004; 11: 1965-1982.
47. Youdim MBH, Finberg JPM, Tipton KF. Catecholamine II. In: Trendelenburg U, Weiner N, Eds. Handbook of experimental pharmacology. Berlin: Springer 1988; pp.127-199.
48. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science 1985; 230: 181-183.
49. O'Carroll AM, Tipton KF, Sullivan JP, Fowler CJ, Ross SB. Intraand extrasynaptosomal deamination of dopamine and noradrenaline by the two forms of human brain monoamine oxidase. Implications for the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in man. Biogenic Amines 1987; 4: 165-178.
50. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006; 7: 295-309.
51. Schifitto G, Yiannoutsos CT, Ernst T, et al.; ACTG 5114 Team. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology 2009; 73: 1975-1981.
52. Evans SR, Yeh TM, Sacktor N, et al. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 2007; 8: 437-446.
53. Magyar K. The pharmacology of selegiline. Int Rev Neurobiol 2011; 100: 65-84.
54. Nandagopal JJ, DelBello MP. Selegiline transdermal system: a novel treatment option for major depressive disorder. Expert Opin Pharmacother 2009; 10: 1665-1673.
55. Chiueh CC, Andoh T, Lai AR, Lai E, Krishna G. Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals. Neurotox Res 2000; 2: 293-310.
56. Mascher HJ, Kikuta C, Millendorfer A, Schiel H, Ludwig G. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. Int J Clin Pharmacol Ther 1997; 35: 9-13.
57. Edelstein SB, Breakefield XO. Monoamine oxidases A and B are differentially regulated by glucocorticoids and 'aging' in human skin fibroblasts. Cell Mol Neurobiol 1986; 6: 121-150.
58. Youdim MBH, Banerjee DK, Kelner K, Offutt L, Pollard HB. Steroid regulation of monoamine oxidase activity in the adrenal medulla. FASEB J 1989; 3:1753-1759.
59. Wichitnithad W, O'Callaghan JP, Miller DB, Train BC, Callery PS. Time-dependent slowly-reversible inhibition of monoamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines. Bioorg Med Chem 2011; 19: 7482-7492.
60. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996; 67: 443-462.
61. Silvers JM, Aksenov MY, Aksenova MV, et al. Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains. J Neurovirol 2006; 12: 140-145.
62. Chang L, Wang GJ, Volkow ND, et al. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage 2008; 42: 869-878.
63. Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM. The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 2009; 159: 1292-9.
64. Popova NK, Vishnivetskaya GB, Ivanova EA, Skrinskaya JA, Seif I. Altered behavior and alcohol tolerance in transgenic mice lacking MAO A: a comparison with effects of MAO A inhibitor clorgyline. Pharmacol Biochem Behav 2000; 67: 719-727.
65. Popova NK, Tibeikina MA. Immobility and hyperthermia in tail suspension test: The association with Porsolt test and startle response in 11 inbred mouse strains, and the effect of MAO A knockout. Zhurnal Vysshei Nervnoi Deyatelnosti Imeni I P Pavlova 2009; 59: 199-205.
66. Zajaczkowski W, Gorka Z. The effects of single and repeated administration of MAO inhibitors on acoustic startle response in rats. Pol J Pharmacol 1993; 45: 157-166.
67. Xu H, Yang HJ, Zhang Y, Clough R, Browning R, Li XM. Behavioral and neurobiological changes in C57BL/6 mice exposed to cuprizone. Behav Neurosci 2009; 123: 418-429.
68. Beyrouty P, Stamler CJ, Liu JN, Loua KM, Kubow S, Chan HM. Effects of prenatal methylmercury exposure on brain monoamine oxidase activity and neurobehavior of rats. Neurotoxicol Teratol 2006; 28: 251-259.
69. Borrell J, Vela J, Arevalo-Martin A, Molina-Holgado E, Guaza C. Prenatal immune challenge disrupts sensorimotor gating in adult rats: Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 2002; 26: 204-215.
70. Aguilar-Valles A, Luheshi GN. Alterations in cognitive function and behavioral response to amphetamine induced by prenatal inflammation are dependent on the stage of pregnancy. Psychoneuroendocrinology 2010; 36: 634-648.
71. Hard E, Engel J, Larsson K, Liljequist S, Musi B. Effects of maternal ethanol consumption on the offspring sensory-motor development, ultrasonic vocalization, audiogenic immobility reaction and brain monoamine synthesis. Acta Pharmacologica et Toxicologica 1985; 56: 354-363.